Skip to content

Inhibrx Biosciences, Inc. INBX Change in Other Assets

Change in Other Assets at other companies

Pfizer logo
PfizerPFE
-$322.25M+61.9%
Nuvation Bio logo
Nuvation BioNUVB
-$3.78M-2,509%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$2.56M+61.0%
Immunome logo
ImmunomeIMNM
$5.1M+199%
Replimune Group logo
Replimune GroupREPL
$94K-88.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s change in other assets?
Inhibrx Biosciences, Inc. (INBX) reported change in other assets of $0 in Q1 2026.
How has Inhibrx Biosciences, Inc.'s change in other assets changed year-over-year?
Inhibrx Biosciences, Inc.'s change in other assets increased by 100.0% year-over-year, from -$28K to $0.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.